[go: up one dir, main page]

ES2160163T3 - Composiciones farmaceuticas a base de derivados de la clase de los taxanos. - Google Patents

Composiciones farmaceuticas a base de derivados de la clase de los taxanos.

Info

Publication number
ES2160163T3
ES2160163T3 ES95918046T ES95918046T ES2160163T3 ES 2160163 T3 ES2160163 T3 ES 2160163T3 ES 95918046 T ES95918046 T ES 95918046T ES 95918046 T ES95918046 T ES 95918046T ES 2160163 T3 ES2160163 T3 ES 2160163T3
Authority
ES
Spain
Prior art keywords
class
derivatives
taxanos
pharmaceutical compositions
compositions based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918046T
Other languages
English (en)
Inventor
Manfred Durr
Jorg-Christian Hager
Armin Wendel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2160163T3 publication Critical patent/ES2160163T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICION FARMACEUTICA ESTABLE Y FUERTEMENTE CONCENTRADA EN PRINCIPIO ACTIVO DE LA CLASE DE LOS TAXOIDES COMO EL DOCETAXEL O LOS DERIVADOS DEL DOCETAXEL, CARACTERIZADA PORQUE COMPRENDE UN AGENTE TERAPEUTICO DE LA CLASE DE LOS TAXOIDES COMO EL DOCETAXEL O LOS DERIVADOS DEL DOCETAXEL, UNO O VARIOS FOSFOLIPIDOS INSATURADOS Y UNA BAJA CANTIDAD DE UNO O VARIOS FOSFOLIPIDOS NEGATIVOS.
ES95918046T 1994-04-25 1995-04-24 Composiciones farmaceuticas a base de derivados de la clase de los taxanos. Expired - Lifetime ES2160163T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9404951A FR2718963B1 (fr) 1994-04-25 1994-04-25 Nouvelle composition pharmaceutique à base de taxoïdes.

Publications (1)

Publication Number Publication Date
ES2160163T3 true ES2160163T3 (es) 2001-11-01

Family

ID=9462475

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95918046T Expired - Lifetime ES2160163T3 (es) 1994-04-25 1995-04-24 Composiciones farmaceuticas a base de derivados de la clase de los taxanos.

Country Status (26)

Country Link
US (1) US5670536A (es)
EP (1) EP0758231B1 (es)
JP (1) JP3950993B2 (es)
KR (1) KR100401119B1 (es)
CN (1) CN1283243C (es)
AT (1) ATE202931T1 (es)
AU (1) AU691283B2 (es)
BR (1) BR9507846A (es)
CZ (1) CZ285720B6 (es)
DE (1) DE69521693T2 (es)
DK (1) DK0758231T3 (es)
ES (1) ES2160163T3 (es)
FI (1) FI118204B (es)
FR (1) FR2718963B1 (es)
GE (1) GEP20002069B (es)
GR (1) GR3036211T3 (es)
HU (1) HU225971B1 (es)
NO (1) NO314745B1 (es)
NZ (1) NZ285122A (es)
PL (1) PL179623B1 (es)
PT (1) PT758231E (es)
RU (1) RU2157200C2 (es)
SK (1) SK283255B6 (es)
TW (1) TW416849B (es)
WO (1) WO1995028923A1 (es)
ZA (1) ZA953358B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
SG113402A1 (en) * 1997-06-27 2005-08-29 American Bioscience Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
TR200002299T2 (tr) * 1998-02-05 2000-11-21 Novartis Ag Epotilon kompozisyonları.
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
RU2213746C1 (ru) * 2002-02-15 2003-10-10 Научно-исследовательский институт физико-химической медицины Компонент, обеспечивающий поверхностно-активные свойства композиций - аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
DE10255285A1 (de) * 2002-11-26 2004-06-03 Mcs Micro Carrier Systems Gmbh Selbst formende Phospholipid-Gele
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2009007992A2 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical composition produced by microprecipitation
EP1987813A1 (en) * 2007-05-04 2008-11-05 Pharmatex Italia Srl Injectable pharmaceutical formulation of taxoids in stable liposomes
RU2370261C2 (ru) * 2007-08-03 2009-10-20 Закрытое Акционерное Общество "Биокад" Стабильная эмульсия для парентерального введения плохо растворимых в воде соединений, обладающих противоопухолевой активностью, и способ ее получения
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
CN101971189A (zh) * 2007-11-07 2011-02-09 爱墨菲特有限公司 压痕泡沫数字扫描仪
RU2370258C2 (ru) * 2007-11-16 2009-10-20 Закрытое Акционерное Общество "Биокад" Фармацевтическая композиция для парентеральной доставки в форме лиофилизата и способ ее получения
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
WO2012156999A1 (en) * 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
DK2875814T3 (en) 2012-07-19 2018-11-12 Fujifilm Corp LIQUID COMPOSITION CONTAINING TAXAN-BASED ACTIVE INGREDIENT, PROCEDURE FOR PREPARING IT AND LIQUID PHARMACEUTICAL COMPOSITION
EA022182B1 (ru) * 2012-12-24 2015-11-30 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы доцетаксела

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
CA2132711C (en) * 1992-03-23 2005-02-08 Aquilar Rahman Liposome encapsulated paclitaxel and a method of using the same
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation

Also Published As

Publication number Publication date
TW416849B (en) 2001-01-01
NO964433L (no) 1996-10-18
PT758231E (pt) 2001-11-30
SK135696A3 (en) 1997-05-07
CZ309396A3 (en) 1997-01-15
FR2718963B1 (fr) 1996-05-24
GR3036211T3 (en) 2001-10-31
FI964285L (fi) 1996-10-24
DE69521693D1 (de) 2001-08-16
JP3950993B2 (ja) 2007-08-01
DK0758231T3 (da) 2001-09-24
SK283255B6 (sk) 2003-04-01
NO314745B1 (no) 2003-05-19
AU2412695A (en) 1995-11-16
FI118204B (fi) 2007-08-31
PL179623B1 (pl) 2000-10-31
EP0758231A1 (fr) 1997-02-19
BR9507846A (pt) 1997-09-16
EP0758231B1 (fr) 2001-07-11
KR970702033A (ko) 1997-05-13
WO1995028923A1 (fr) 1995-11-02
NZ285122A (en) 1998-06-26
ATE202931T1 (de) 2001-07-15
CZ285720B6 (cs) 1999-10-13
CN1146722A (zh) 1997-04-02
CN1283243C (zh) 2006-11-08
GEP20002069B (en) 2000-05-10
KR100401119B1 (ko) 2004-03-19
HU9602942D0 (en) 1996-12-30
DE69521693T2 (de) 2002-05-02
JPH09512261A (ja) 1997-12-09
HU225971B1 (en) 2008-01-28
AU691283B2 (en) 1998-05-14
HUT75513A (en) 1997-05-28
US5670536A (en) 1997-09-23
RU2157200C2 (ru) 2000-10-10
ZA953358B (en) 1996-01-17
FR2718963A1 (fr) 1995-10-27
FI964285A0 (fi) 1996-10-24
PL316942A1 (en) 1997-02-17
NO964433D0 (no) 1996-10-18

Similar Documents

Publication Publication Date Title
ES2160163T3 (es) Composiciones farmaceuticas a base de derivados de la clase de los taxanos.
CL2004000931A1 (es) Pelicula consumible adaptada para adherirse y disolverse en la cavidad bucal que comprende un almidon modificado y un agente farmaceuticamente activo.
DE60312523D1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
ES2099094T3 (es) Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos.
CY1110949T1 (el) Σταθεροποιημενες με πηκτωμα συνθεσεις νανοσωματιδιακων δραστικων παραγοντων
PA8601401A1 (es) Peliculas consumibles por via oral que se disuelven rapidamiente, que contienen un edulcorante
ES2185595T3 (es) Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
ES2125734T3 (es) Utilizacion de un 2-amino-alcano-1,3-diol para frenar la caida de los cabellos y/o inducir y estimular su crecimiento.
CO2023009176A2 (es) Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
MEP7809A (en) Use of docetaxel for treating hepatocellular carcinoma
CO5241355A1 (es) Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
AR005970A1 (es) Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
ES2191426T3 (es) Composiciones estables que comprenden levosimendano y acido alginico.
DE602004029453D1 (de) Auf licht reagierende duftstoffe
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 758231

Country of ref document: ES